Registered Nurse in Anasco, PR Accepting Medicare
4 Registered Nurse nurses found. Showing 1 - 4
 Xiomara Perez, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Car 109 Km 1.3, Anasco, PR 00610 Phone: 787-438-2129 |
Mayrabeth Atilano Collazo, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Carretera 405 Km 2.4, Barrio Carreras, Anasco, PR 00610 Phone: 970-402-1284 |
 Fernando Pesante Acevedo I, BSN Registered Nurse - Home Health Medicare: Not Enrolled in Medicare Practice Location: Rr 3 Box 10464, Anasco, PR 00610 Phone: 787-436-1380 |
Maribel Villanueva, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Calle San Antonio # 17, Anasco, PR 00610 Phone: 787-868-2442 |
News Archive
CellAura to provide pharmacologically validated reagents for Cisbio Bioassays' cellular studies
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Experts develop innovative technologies to improve healthcare and border security
With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS).
Swander Pace Capital sells Insight Pharmaceuticals to Prestige Brands Holdings for $750 million
Swander Pace Capital, a leading private equity firm specializing in investments in consumer products companies, announced today that it is selling its over-the-counter (OTC) products portfolio company, Insight Pharmaceuticals, to Prestige Brands Holdings for $750 million.
FDA-approved cancer drug blunts SARS-CoV-2 protein's detrimental effects
University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2-;the virus that causes COVID-19 – and then used an FDA-approved cancer drug to blunt the viral protein's detrimental effects. In their experiments in fruit flies and human cell lines, the team discovered the cell process that the virus hijacks, illuminating new potential candidate drugs that could be tested for treating severe COVID-19 disease patients.
› Verified 3 days ago